Related Experiment Videos
Levocarnitine and dialysis: a review.
1Dialysis Care, Department of Medicine, Division of Nephrology, Medical College of Wisconsin, Milwaukee, WI, USA. bdschreib@new.rr.com
Summary
Dialysis patients often have fatty acid metabolism issues, leading to health problems. Levocarnitine supplementation may help improve these conditions and reduce patient morbidity.
Area of Science:
- Nephrology
- Metabolic Medicine
- Biochemistry
Background:
- Dialysis patients exhibit metabolic abnormalities, particularly in fatty acid metabolism.
- Defective fatty acid metabolism contributes to oxidative stress, insulin resistance, and apoptosis, increasing morbidity.
- Carnitine deficiency is common in hemodialysis and peritoneal dialysis patients.
Purpose of the Study:
- To review evidence of carnitine deficiency in dialysis patients.
- To examine clinical trial data on levocarnitine therapy efficacy.
- To summarize and contrast expert recommendations with current guidelines for levocarnitine access.
Main Methods:
- Literature review of studies on carnitine metabolism in dialysis patients.
- Analysis of clinical trials investigating levocarnitine's effects on dialysis-related conditions.
- Synthesis of consensus recommendations and current access guidelines.
Main Results:
- Dialysis patients often present with carnitine deficiency, indicated by low plasma free carnitine and altered acyl:free carnitine ratio.
- Levocarnitine therapy has been studied for skeletal muscle weakness, cardiomyopathy, hypotension, hyperlipidemia, and anemia.
- Evidence suggests levocarnitine can mitigate some adverse effects of defective fatty acid metabolism.
Conclusions:
- Carnitine deficiency is a significant issue in dialysis populations.
- Levocarnitine supplementation shows potential therapeutic benefits for various complications.
- Further clarification of consensus recommendations versus current guidelines for levocarnitine access is needed.